Foretell My Health provides early cancer detection through a liquid biopsy that analyzes platelet RNA signatures. This novel approach identifies tumor-educated platelets (TEPs) to detect OB/GYN cancers, including ovarian and uterine tumors, at earlier stages than traditional methods.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional liquid biopsy methods often struggle with detecting early-stage cancers due to low circulating tumor DNA (ctDNA) levels. This limitation hinders the effectiveness of screening for cancers that lack robust early detection methods, impacting patient outcomes.
Solution
Foretell My Health offers an early cancer detection solution utilizing a novel liquid biopsy technology that analyzes platelet RNA signatures. This approach leverages tumor-educated platelets (TEPs) as biomarkers, detecting cancer at earlier stages than many ctDNA-based methods. The service focuses on OB/GYN cancers, including ovarian and uterine tumors, by processing a single blood draw to extract RNA, convert it to sequencing data, and apply proprietary diagnostic algorithms. This enables accessible screening as part of routine health checkups, aiming to improve survival rates through earlier intervention.
Target Audience
The primary target audience includes individuals seeking proactive cancer screening, particularly for OB/GYN cancers, and healthcare providers looking for advanced diagnostic tools for early detection.
Features
- Multiplexed TEP (Tumor-Educated Platelet) RNA analysis for early cancer detection.
- Utilizes advanced sequencing and proprietary AI algorithms for biomarker analysis.
- Specifically targets OB/GYN cancers, including early-stage ovarian and uterine tumors.
- Demonstrates an estimated 5x increase in early detection (Stage I and II) compared to conventional methods.
- Projected to improve survival rates by 36% through early intervention.
- Developed through collaborative clinical research and patent filings.